Final FDA Guidance Delivers More Digestible Tablet Chewing Index
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
You may also be interested in...
Chewable Tablet Adverse Events, Manufacturing Slips Prompt Guidance
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance document. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.